WASHINGTON— Federal health regulators have approved a second vaccine to prevent a strain of bacteria that can cause deadly cases of meningitis. The Food and Drug Administration said it cleared Novartis' Bexsero vaccine against a subtype of meningococcal bacteria in people ages 10 to 25. The agency cleared a similar vaccine from Pfizer last October.» Read More
Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.
Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.
Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.
Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans.
PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.
Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..
The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.
CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.
LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.
WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.
NEW YORK, Aug 20- An experimental drug from Tekmira Pharmaceuticals Corp helped lab monkeys recover from the most deadly strain of Marburg virus, a close cousin of Ebola, even after symptoms appeared, scientists reported on Wednesday.
LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.
*Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies has raised questions about who gets priority access to treatment.
*Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies raises questions about who gets priority access to treatment.
LONDON, Aug 12- World Health Organization experts fighting the world's worst outbreak of Ebola hope for improved supplies of experimental treatments and progress with a vaccine by the end of the year.
The Ebola epidemic in West Africa has killed nearly 1,000 people and prompted the World Health Organization to declare an international health emergency. GSK is co-developing a vaccine with the U.S. National Institute of Allergy and Infectious Diseases, which has shown promising results in primates.
U.S. biotech firm Celladon hopes that its Mydicar treatment can help patients like Lee Adams who have advanced heart failure and rely on so called Left Ventricular Assist Devices to keep them alive until a donor heart becomes available.
LONDON, Aug 10- A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists.
U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.
The World Health Organization has declared the West African epidemic a public health emergency, reviving interest in antiviral drugs that could treat Ebola. Companies such as Tekmira Pharmaceutical Corp, BioCryst Pharmaceuticals Inc and NanoViricides Inc have drugs that are still in pre-clinical trials, meaning they are yet to be tested in humans.